Grants4Apps Accelerator and new Dealmaker now open for submissions

The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.

Grants4Apps Accelerator Berlin 2017

Startups receive € 50,000 each as well as office space in the Bayer Pharmaceuticals Headquarters. Additionally, C-level mentors will support in refining business models, validating technologies and more.

The Grants4Apps team is looking for startups with innovative healthcare solutions. The team is open for any healthcare topics and will give special attention to Bayer-relevant focus areas. This year Grants4Apps is focusing on digital health solutions in the areas of Nephrology (e.g., Chronic Kidney Disease), Women's Health (e.g., Endometriosis), Pulmonology (e.g., Pulmonary Hypertension), Cardiology (e.g., Atrial Fibrillation), Hematology, Oncology, Radiology, Infectious Diseases and Ophthalmology (e.g., Diabetic Retinopathy).

Grants4Apps is also calling for collaboration projects using software or hardware to be applied in clinical trials and medical IT using state-of-the art-technologies such as artificial intelligence, machine learning, deep learning, sophisticated algorithms, bioinformatics, genomics analysis, novel approaches for Electronic Health Records (EHR) etc. - in short: highly innovative technologies with a taste for excellent simplicity and unbeatable user experience focus.

Submission deadline: 31 May 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/accelerator-berlin-2017/

Dealmaker Berlin 2017

Don't need acceleration? Want to gain Bayer as a potential customer? Then this is for you! Mature startups can apply to solve specific 'Bayer challenges'. The top startup matches will have the opportunity to come to Berlin in September (travelling costs will be covered by Bayer) and to sign a potential project deal, please find the challenge you can solve.

If there is a match, you will be inviteed to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Applicants are asked to address one or multiple challenges. However, the Dealmaker is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]